Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06259552 · ClinicalTrials.gov registry record · Phase 1
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
A Phase 1 study of Solid Tumor and HNSCC, sponsored by SparX Biotech(Jiangsu) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 232
- Enrollment target
- 4
- Study locations
NCT06259552 is a Phase 1 study of Solid Tumor and HNSCC that is actively recruiting participants, run by SparX Biotech(Jiangsu) Co.. The registered enrollment target is 232 participants, roughly in line with the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target. The trial reports 4 study locations across 3 states.
The verdict
NCT06259552, a Phase 1 study of Solid Tumor and HNSCC, is actively recruiting participants, sponsored by SparX Biotech(Jiangsu) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 232 participants
- Enrollment target
- 4
- Study locations
Study Summary
Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.
Conditions Studied
Interventions
- BIOLOGICAL SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody
Study Locations (4)
Arizona
- Mayo Clinic Arizona - Phoenix
- HonorHealth Research and Innovation Institute - Scottsdale
Florida
- Mayo Clinic Florida - Jacksonville
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2024-03-20 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06259552
The ClinicalTrials.gov registry entry for NCT06259552 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target. The listed sponsor is SparX Biotech(Jiangsu) Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody is the first listed.
NCT06259552 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06259552 about?
NCT06259552 is a clinical study titled "A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors". Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.
What is the current status of trial NCT06259552?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 232 participants. The study started on 2024-03-20. Estimated completion is 2027-09.
What conditions does trial NCT06259552 study?
This clinical trial studies the following conditions: Solid Tumor, HNSCC, CRC, RCC.
What interventions are being tested in trial NCT06259552?
The interventions under investigation include: SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT06259552?
This trial is sponsored by SparX Biotech(Jiangsu) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06259552 being conducted?
This trial has 4 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.